How (if at all) would you consider incorporating alpelisib in metastatic, HR+, PIK3CA mutated breast cancer in a patient who previously progressed on fulvestrant?

This question will hopefully be partially answered by the ongoing BYLieve study, which includes a cohort of patients who have previously progressed on fulvestrant with CDK4/6 inhibition. This study is currently enrolling and open nationally (NCT03056755).

While awaiting those results, and assuming t...